...
search icon
lyel-img

Lyell Immunopharma Inc, Common Stock

LYEL

NSQ

$0.46

+$0.02

(4.57%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$135.45M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
476.46K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.39 L
$2.88 H
$0.46

About Lyell Immunopharma Inc, Common Stock

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLYELSectorS&P500
1-Week Return0.26%-1.91%-4.4%
1-Month Return-17.74%-8.22%-10.77%
3-Month Return-20.14%-5.01%-15.29%
6-Month Return-60%-10.62%-11.9%
1-Year Return-80.91%-3.17%2.9%
3-Year Return-91.15%1.04%20.61%
5-Year Return-97.28%37.23%84.18%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue7.76M10.65M84.68M130.00K61.00K[{"date":"2020-12-31","value":9.16,"profit":true},{"date":"2021-12-31","value":12.58,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.15,"profit":true},{"date":"2024-12-31","value":0.07,"profit":true}]
Cost of Revenue7.47M14.54M16.47M20.25M-[{"date":"2020-12-31","value":36.91,"profit":true},{"date":"2021-12-31","value":71.78,"profit":true},{"date":"2022-12-31","value":81.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit281.00K(3.88M)68.22M130.00K61.00K[{"date":"2020-12-31","value":0.41,"profit":true},{"date":"2021-12-31","value":-5.7,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.19,"profit":true},{"date":"2024-12-31","value":0.09,"profit":true}]
Gross Margin3.62%(36.48%)80.55%100.00%100.00%[{"date":"2020-12-31","value":3.62,"profit":true},{"date":"2021-12-31","value":-36.48,"profit":false},{"date":"2022-12-31","value":80.55,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses219.69M225.43M276.50M247.14M358.82M[{"date":"2020-12-31","value":61.23,"profit":true},{"date":"2021-12-31","value":62.82,"profit":true},{"date":"2022-12-31","value":77.06,"profit":true},{"date":"2023-12-31","value":68.88,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(211.94M)(214.78M)(183.12M)(247.01M)(3.31M)[{"date":"2020-12-31","value":-21193700000,"profit":false},{"date":"2021-12-31","value":-21477600000,"profit":false},{"date":"2022-12-31","value":-18311800000,"profit":false},{"date":"2023-12-31","value":-24700800000,"profit":false},{"date":"2024-12-31","value":-330900000,"profit":false}]
Total Non-Operating Income/Expense13.40M(35.49M)10.89M35.83M(315.62M)[{"date":"2020-12-31","value":37.41,"profit":true},{"date":"2021-12-31","value":-99.05,"profit":false},{"date":"2022-12-31","value":30.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-880.9,"profit":false}]
Pre-Tax Income(204.47M)(250.22M)(183.12M)(234.63M)(342.99M)[{"date":"2020-12-31","value":-20447200000,"profit":false},{"date":"2021-12-31","value":-25021900000,"profit":false},{"date":"2022-12-31","value":-18311800000,"profit":false},{"date":"2023-12-31","value":-23463200000,"profit":false},{"date":"2024-12-31","value":-34299400000,"profit":false}]
Income Taxes(5.94M)35.28M(178.36M)(10.53M)-[{"date":"2020-12-31","value":-16.83,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-505.54,"profit":false},{"date":"2023-12-31","value":-29.85,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(198.53M)(285.50M)(4.75M)(224.10M)-[{"date":"2020-12-31","value":-19853300000,"profit":false},{"date":"2021-12-31","value":-28550100000,"profit":false},{"date":"2022-12-31","value":-475400000,"profit":false},{"date":"2023-12-31","value":-22410200000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(204.47M)(250.22M)(183.12M)(234.63M)(342.99M)[{"date":"2020-12-31","value":-20447200000,"profit":false},{"date":"2021-12-31","value":-25021900000,"profit":false},{"date":"2022-12-31","value":-18311800000,"profit":false},{"date":"2023-12-31","value":-23463200000,"profit":false},{"date":"2024-12-31","value":-34299400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(198.53M)(285.50M)(4.75M)(234.63M)(342.99M)[{"date":"2020-12-31","value":-19853300000,"profit":false},{"date":"2021-12-31","value":-28550100000,"profit":false},{"date":"2022-12-31","value":-475400000,"profit":false},{"date":"2023-12-31","value":-23463200000,"profit":false},{"date":"2024-12-31","value":-34299400000,"profit":false}]
EPS (Diluted)(3.19)(2.28)(0.75)(0.78)(0.67)[{"date":"2020-12-31","value":-318.68,"profit":false},{"date":"2021-12-31","value":-228,"profit":false},{"date":"2022-12-31","value":-75,"profit":false},{"date":"2023-12-31","value":-78,"profit":false},{"date":"2024-12-31","value":-67.21,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LYEL
Cash Ratio 6.89
Current Ratio 7.06

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LYEL
ROA (LTM) -22.05%
ROE (LTM) -66.10%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LYEL
Debt Ratio Lower is generally better. Negative is bad. 0.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.78

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LYEL
Trailing PE NM
Forward PE NM
P/S (TTM) 2118.39
P/B 0.33
Price/FCF NM
EV/R 1938.09
EV/Ebitda 0.25

FAQs

What is Lyell Immunopharma Inc share price today?

Lyell Immunopharma Inc (LYEL) share price today is $0.46

Can Indians buy Lyell Immunopharma Inc shares?

Yes, Indians can buy shares of Lyell Immunopharma Inc (LYEL) on Vested. To buy Lyell Immunopharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LYEL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lyell Immunopharma Inc be purchased?

Yes, you can purchase fractional shares of Lyell Immunopharma Inc (LYEL) via the Vested app. You can start investing in Lyell Immunopharma Inc (LYEL) with a minimum investment of $1.

How to invest in Lyell Immunopharma Inc shares from India?

You can invest in shares of Lyell Immunopharma Inc (LYEL) via Vested in three simple steps:

  • Click on Sign Up or Invest in LYEL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lyell Immunopharma Inc shares
What is Lyell Immunopharma Inc 52-week high and low stock price?

The 52-week high price of Lyell Immunopharma Inc (LYEL) is $2.88. The 52-week low price of Lyell Immunopharma Inc (LYEL) is $0.39.

What is Lyell Immunopharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lyell Immunopharma Inc (LYEL) is 0.33

What is the Market Cap of Lyell Immunopharma Inc?

The market capitalization of Lyell Immunopharma Inc (LYEL) is $135.45M

What is Lyell Immunopharma Inc’s stock symbol?

The stock symbol (or ticker) of Lyell Immunopharma Inc is LYEL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top